BioCardia Completes FDA Pre-Submission for Helix Catheter, Paving Way for Potential Approval
BCDA sits 27% above its 52-week low of $1.
Summary
BioCardia announced the completion of its FDA Pre-Submission for the Helix Transendocardial Delivery Catheter, a critical step towards potential market approval for its therapeutic delivery system.
Key Events · Product Development and Regulatory · BCDA
-
FDA Pre-Submission Completed
BioCardia, Inc. has completed its Pre-Submission to the U.S. Food and Drug Administration (FDA) for the approval of its Helix Transendocardial Delivery Catheter, intended for intramyocardial therapeutic and diagnostic agent delivery.
-
Strategic Regulatory Pathway
The Pre-Submission was made under the CardiAMP Cell Therapy System FDA Breakthrough Designation, aiming to align with the FDA on the regulatory pathway and timing for approval within 45 days, potentially leading to a market clearance application soon.
-
Enabling Technology for Cell Therapies
The Helix catheter is described as an enabling platform, with CEO Peter Altman stating its approval would streamline future FDA approvals for BioCardia's autologous and allogeneic cell therapies for heart failure and chronic myocardial ischemia, and reduce development risk for potential partners.
-
Supported by Clinical Data
The submission is supported by safety and effectiveness data from fifteen well-controlled clinical trials involving cell and gene therapy delivery to the heart across three primary cardiac indications.
Analysis · BCDA · Life Sciences
This filing signals a crucial step forward in BioCardia's regulatory strategy for its Helix Transendocardial Delivery Catheter. Completing the FDA Pre-Submission under the Q-Submission program is a formal process to align with the FDA on the regulatory pathway and timing for approval. For a life sciences company, especially one with a relatively small market capitalization, advancing a core delivery technology like Helix, which underlies its breakthrough-designated CardiAMP Cell Therapy System, is highly important. The CEO's statement highlights the strategic goal of making Helix the first approved transendocardial delivery catheter system in the U.S., which would significantly streamline future approvals for BioCardia's cell therapies and potentially attract biopharmaceutical partners.
At the time of this filing, BCDA was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.00 to $3.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.